Market research
CNSP CNS Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 0.98
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US18978H1023
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- 0.98
About
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CNSP discussion.
5 years, 4 months ago
CNS Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 17.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
CNS Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 18.9% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 41.8% to $-1M since the same quarter in the previous year.
Based on the above factors, CNS Pharmaceuticals, Inc gets an overall score of 2/5.